Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.
Reunion Neuroscience has raised $68.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2025.
Reunion Neuroscience's investors include Novo Holdings, MPM Capital, Palo Santo Fund, FemHealth Ventures, Mitsui Global Investment.
Reunion Neuroscience is headquartered in Toronto, Canada.
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions.
Reunion Neuroscience is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Reunion Neuroscience — Funding & Investors." VCBacked, May 5, 2025, https://www.vcbacked.co/company/reunion-neuroscience. Accessed November 4, 2026.
VCBacked. (2025). Reunion Neuroscience — Funding & Investors. Retrieved November 4, 2026, from https://www.vcbacked.co/company/reunion-neuroscience
{{cite web |title=Reunion Neuroscience — Funding & Investors |url=https://www.vcbacked.co/company/reunion-neuroscience |website=VCBacked |access-date=November 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Reunion Neuroscience? Request a listing update